Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: Myelodysplastic syndromes (MDS) are a group of heterogeneous diseases with variable clinical course. Predicting disease progression is difficult due to lack of specific molecular marker(s). SALL4 plays important roles in normal hematopoiesis and leukemogenesis. SALL4 transgenic mice develop MDS prior to acute myeloid leukemia (AML) transformation. However, the role of SALL4 in human MDS has not been extensively investigated. In this study, we evaluate the diagnostic/prognostic value of SALL4 in MDS by examining its expression levels in a cohort of MDS patients. Methods: Fifty-five newly diagnosed MDS, twenty MDS-AML, and sixteen post-treatment MDS patients were selected for our study along with ten healthy donors. Results: We demonstrated that SALL4 was over-expressed in MDS patients and proportionally increased in MDS patients with high grade/IPSS scores. This expression pattern was similar to that of Bmi-1, an important marker in predicting MDS/AML progression. In addition, the level of SALL4 was positively correlated with increased blast counts, high-risk keryotypes and increased significantly in MDS-AML transformation. Furthermore, higher level of SALL4 expression was associated with worse survival rates and SALL4 level decreased following effective therapy. Conclusions: To the best of our knowledge, this is the largest series and the first to report the expression pattern of SALL4 in detail in various subtypes of MDS in comparison to that of Bmi-1. We conclude that SALL4 is a potential molecular marker in predicting the prognosis of MDS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells.
Park, I.-K., Qian, D., Kiel, M., Becker, M. W., Pihalja, M., Weissman, I. L., Morrison, S. J., & Clarke, M. F. (2003) · Nature · doi:10.1038/nature01587 · Cited by 1,871
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627
Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells.
Lessard, J., & Sauvageau, G. (2003) · Nature · doi:10.1038/nature01572 · Cited by 1,452 · cited 1×
“Bmi-1 is a member of the polycomb repression complex, and is required for the maintenance and selfrenewal of normal and leukemic stem and progenitor cells [28-30].”
BackgroundRecurrent DNMT3A mutations in patients with myelodysplastic syndromes
Walter, M. J., Ding, L., Shen, D., Shao, J., Grillot, M., McLellan, M., Fulton, R., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., et al. (2011) · Leukemia · doi:10.1038/leu.2011.44 · Cited by 527
Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1
Iwama, A., Oguro, H., Negishi, M., Kato, Y., Morita, Y., Tsukui, H., Ema, H., Kamijo, T., Katoh-Fukui, Y., Koseki, H., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.11.004 · Cited by 515
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8576 · Cited by 463
Oncofetal Gene SALL4 in Aggressive Hepatocellular Carcinoma
Yong, K. J., Gao, C., Lim, J. S. J., Yan, B., Yang, H., Dimitrov, T., Kawasaki, A., Ong, C. W., Wong, K.-F., Lee, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300297 · Cited by 257
Self-citationMa, Y., Cui, W., Yang, J., Qu, J., Di, C., Amin, H. M., Lai, R., Ritz, J., Krause, D. S., & Chai, L. (2006) · Blood · doi:10.1182/blood-2006-02-001594 · Cited by 215
Self-citationSALL4 is a key regulator of survival and apoptosis in human leukemic cells
Yang, J., Chai, L., Gao, C., Fowles, T. C., Alipio, Z., Dang, H., Xu, D., Fink, L. M., Ward, D. C., & Ma, Y. (2008) · Blood · doi:10.1182/blood-2007-11-126326 · Cited by 132 · cited 1×
“SALL4 is an important embryonic stem cell (ESC) factor that is also involved in normal hematopoiesis, leukemogenesis [12-20], hepatocellular carcinoma [21-23] and infantile hemangiomas [24].”
BackgroundSelf-citationSALL4 is a key transcription regulator in normal human hematopoiesis
Gao, C., Kong, N. R., Li, A., Tatetu, H., Ueno, S., Yang, Y., He, J., Yang, J., Ma, Y., Kao, G. S., et al. (2013) · Transfusion · doi:10.1111/j.1537-2995.2012.03888.x · Cited by 58 · cited 2×
“SALL4 is an important embryonic stem cell (ESC) factor that is also involved in normal hematopoiesis, leukemogenesis [12-20], hepatocellular carcinoma [21-23] and infantile hemangiomas [24].”
BackgroundSelf-citation
Cited by
SALL4, the missing link between stem cells, development and cancer
Tatetsu, H., Kong, N. R., Chong, G., Amabile, G., Tenen, D. G., & Chai, L. (2016) · Gene · doi:10.1016/j.gene.2016.02.019 · Cited by 130
Self-citationSALL4: An Intriguing Therapeutic Target in Cancer Treatment
Moein, S., Tenen, D. G., Amabile, G., & Chai, L. (2022) · Cells · doi:10.3390/cells11162601 · Cited by 35
“Our findings showed that the level of SALL4 expression is positively correlated with karyotype abnormalities, poor survival, and an increased risk of MDS to AML transformation [39,40].”
BackgroundSelf-citationLeukemic survival factor SALL4 contributes to defective DNA damage repair
Wang, F., Gao, C., Lu, J., Tatetsu, H., Williams, D. A., Müller, L. U., Cui, W., & Chai, L. (2016) · Oncogene · doi:10.1038/onc.2016.146 · Cited by 17
“While SALL4 expression is down regulated during development, and not detectable in most human adult tissues, it is aberrantly expressed in high-grade MDS patients (11) and most AML patients(12).”
InfluentialSelf-citationDissecting the cell of origin of aberrant SALL4 expression in myelodysplastic syndrome
Tatetsu, H., Watanabe, M., Liu, J., Tokunaga, K., Iwanaga, E., Komohara, Y., Thrash, E., Bassal, M. A., Matsuoka, M., Tenen, D. G., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1327 · Cited by 1
“2),-18,-20 +mar1,mar2,mar3[12]/46,XY[3] GNAS, GATA2, KMT2C, TP53 56.”
Self-citation
Metadata
- Authors
- Wang, F., Guo, Y., Chen, Q., Yang, Z., Ning, N., Zhang, Y., Xu, Y., Xu, X., Tong, C., Chai, L., & Cui, W.
- Venue
- Journal of Hematology & Oncology
- Published
- 2013-09-26
- Volume
- 6
- Issue
- 1
- Pages
- 73-73
- ISSN
- 1756-8722 (ISSN-L)
- OpenAlex
- W2110795506
- Cited by
- 32
- References
- 11
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes. https://app.cochat.ai/papers/10.1186/1756-8722-6-73
- The paper
- Wang, F., Guo, Y., Chen, Q., Yang, Z., Ning, N., Zhang, Y., Xu, Y., Xu, X., Tong, C., Chai, L., & Cui, W. (2013). Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes. Journal of Hematology & Oncology. https://doi.org/10.1186/1756-8722-6-73
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.